Commonwealth Equity Services LLC trimmed its position in GE HealthCare Technologies by 34.4% during the third quarter, selling 91,088 shares and ending the period with 173,486 shares. The divestiture reduced Commonwealth’s holding to approximately $13.0 million in market value, according to the firm’s latest 13F filing. This move follows a broader trend of portfolio rebalancing among institutional investors, with National Bank of Canada FI more than doubling its stake to hold nearly 900,000 shares and Wedge Capital Management establishing a new position valued at nearly $27 million.

In the quarter ended September 30, GE HealthCare reported revenue of $5.14 billion, up 5.8% year-over-year, and delivered earnings per share of $1.07, exceeding consensus estimates by $0.02. The company achieved a net margin of 10.94% and a return on equity of 22.52%. For fiscal year 2025, management reaffirmed guidance of between $4.51 and $4.63 per share, implying mid-single-digit revenue growth driven by strength in diagnostic imaging and services.

GE HealthCare declared a quarterly dividend of $0.035 per share, payable February 13 to shareholders of record as of January 9. At the current payout, the company’s annualized dividend amounts to $0.14 per share, representing roughly a 3% payout ratio against projected full-year earnings, underscoring management’s emphasis on balancing shareholder returns with reinvestment in R&D and capacity expansion.

Equity research coverage remains balanced, with seven analysts assigning Buy ratings and seven maintaining Holds, resulting in a Moderate Buy consensus. Price targets among the major brokerages range narrowly around the high-single-digit upside, reflecting confidence in GE HealthCare’s leading position in diagnostic imaging and robust service business, while acknowledging potential margin pressure from regulatory headwinds and ongoing investments in next-generation imaging platforms.